Arka Chatterjee
- Associate Professor, Medicine - (Clinical Scholar Track)
- (520) 626-8927
- AHSC, Rm. 5156
- arkachatterjee@arizona.edu
Biography
Dr. Chatterjee joined Banner University Medical Center - Tucson as the Associate / Interim Director for Structural Heart disease after being an integral part of a high-volume structural program at the University of Alabama at Birmingham. He originally hails from India and completed medical school at the University of Delhi followed by a residency at the University of Louisville. He underwent cardiology and interventional cardiology fellowships at the University of Alabama at Birmingham, where he then joined the faculty in 2016. In his first year on faculty, he was trained on structural and congenital procedures by both adult and pediatric interventionist mentors, gaining an experience which is extremely rare for adult cardiologists. Subsequently he was a key part of both the adult structural and adult congenital interventional programs. He is experienced in transcatheter therapies for valvular disease and other congenital / structural heart defects. He finds the best part of working in the structural heart team is the necessity of a team structure - different specialty physicians / surgeons, advanced providers all working to find the best treatment pathway for each individual patient.
At Banner, Dr. Chatterjee has been instrumental in improving both the volumes and quality outcomes of the structural heart programs leading to a 200-300% increase in the patients treated for structural heart issues with negligible complications.
Degrees
- M.D. Medical Doctor
- University of Delhi (Maulana Azad Medical College), New Delhi, India
Work Experience
- University of Arizona College of Medicine, Tucson, Arizona (2020 - Ongoing)
Awards
- SCAI "30 in their 30s" Award
- Society for Cardiovascular Angiography and Intervention, Spring 2023
- Best Teacher Award
- General Cardiology Fellowship Program, Summer 2020
- Best of the Best Abstract Award
- Society for Cardiovascular Angiography and Interventions Scientific Session 2016 Conference, Spring 2016
Licensure & Certification
- Testamur, National Board of Echocardiography (2014)
- Alabama Medical License, Alabama Board of Medical Examiners & Medical Licensure Commission (2012)
- Cardiovascular Disease, American Board of Internal Medicine (2015)
- Internal Medicine, American Board of Internal Medicine (2012)
- Interventional Cardiology, American Board of Internal Medicine (2016)
Interests
Research
Database research for procedural outcomes.
Teaching
Resident and Fellow education.
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Acharya, D., Kazui, T., Al Rameni, D., Acharya, T., Betterton, E., Juneman, E., Loyaga-Rendon, R., Lotun, K., Shetty, R., & Chatterjee, A. (2023). Aortic valve disorders and left ventricular assist devices. Frontiers in cardiovascular medicine, 10, 1098348.More infoAortic valve disorders are important considerations in advanced heart failure patients being evaluated for left ventricular assist devices (LVAD) and those on LVAD support. Aortic insufficiency (AI) can be present prior to LVAD implantation or develop during LVAD support. It is usually a progressive disorder and can lead to impaired LVAD effectiveness and heart failure symptoms. Severe AI is associated with worsening hemodynamics, increased hospitalizations, and decreased survival in LVAD patients. Diagnosis is made with echocardiographic, device assessment, and/or catheterization studies. Standard echocardiographic criteria for AI are insufficient for accurate diagnosis of AI severity. Management of pre-existing AI includes aortic repair or replacement at the time of LVAD implant. Management of AI on LVAD support is challenging with increased risks of repeat surgical intervention, and percutaneous techniques including transcatheter aortic valve replacement are assuming greater importance. In this manuscript, we provide a comprehensive approach to contemporary diagnosis and management of aortic valve disorders in the setting of LVAD therapy.
- Chatterjee, A., Kazui, T., & Acharya, D. (2023). Growing prevalence of aortic stenosis - Question of age or better recognition?. International journal of cardiology, 388, 131155.
- Leesar, M. A., Waheed, S., Al Solaiman, F., Chatterjee, A., Daya, H. A., Hage, F. G., & Brott, B. C. (2023). Randomized trial of an oblique versus standard fluoroscopic-guided micropuncture technique for femoral arterial access: The Micropuncture-CFA trial. Cardiovascular revascularization medicine : including molecular interventions, 57, 43-50.More infoThe anterior-posterior fluoroscopic guidance (the AP technique) is a standard method for common femoral artery (CFA) access, but the rate of CFA access with ultrasound vs. the AP technique was not significantly different. We have shown an oblique fluoroscopic guidance (the oblique technique) with a micropuncture needle (MPN) resulted in CFA access in 100 % of patients. The outcome of the oblique vs. AP technique is unknown. We compared the utilities of the oblique vs. AP technique for CFA access with a MPN in patients undergoing coronary procedures.
- Warner, E. D., Riley, J., Liotta, M., Pritting, C., Brailovsky, Y., Jimenez, D., Chatterjee, A., Tchantchaleishvili, V., & Rajapreyar, I. N. (2023). Aortic Valve Replacement in Patients With ESRD and Heart Failure With Reduced Ejection Fraction. The American journal of cardiology, 205, 111-119.More infoTranscatheter aortic valve replacement (TAVR) has become the standard of care for the treatment of all patients with calcific aortic stenosis. Patients with end-stage renal disease (ESRD) on hemodialysis were excluded from participation in many of the seminal trials proving the safety and efficacy of TAVR. The outcomes of TAVR in the ESRD population from a national registry showed significantly higher in-hospital and 1-year mortality compared with patients not on hemodialysis. Comparisons of outcomes for surgical versus transcatheter interventions in patients with ESRD and heart failure with reduced ejection fraction (HFrEF) are limited. Using the United States Renal Data System, we identified all ESRD patients with aortic stenosis and HFrEF who underwent TAVR, surgical aortic valve replacement (SAVR), or those with HFrEF and aortic stenosis initiated on dialysis after the year 2012 to compare survival. Propensity score matching was performed, and groups were compared using Kaplan-Meier curves. The study population consisted of 7,660 patients, of which 5,064 (66.1%) were male. The median age at initiation of dialysis was 73 years (interquartile range: 65 to 80). There were 1,108 (14.5%) who underwent TAVR and 695 (9.1%) who underwent SAVR. After matching, patients who underwent TAVR had increased survival relative to those who were medically managed. In-hospital outcomes favored TAVR with less mortality and fewer complications when compared with SAVR. TAVR had improved mortality relative to SAVR in the early period, but survival curves crossed at approximately 9 months and SAVR had better mortality in the long-term. TAVR is a safe and effective procedure and is associated with improved mortality when compared with medical management. In conclusion, TAVR and SAVR are both viable options for patients with ESRD and HF with TAVR having better short-term outcomes and SAVR better long-term outcomes.
- Ajmal, M., Chatterjee, A., & Acharya, D. (2022). Persistent or Recurrent Angina Following Percutaneous Coronary Revascularization. Current cardiology reports, 24(12), 1837-1848.More infoPersistent or recurrent angina after percutaneous coronary intervention (PCI) has substantial patient morbidity and economic impact. As knowledge of the pathophysiology of this condition has evolved, new tools for accurate diagnosis and treatment have become available. We provide a current, comprehensive review of mechanisms of post-PCI angina, diagnostic strategies, and therapeutic options.
- Bhattacharyya, N., Singh, S., Mukherjee, D., Das, N., Chatterjee, A., Adhikari, A., Mondal, S., Mondal, P., Mallick, A. K., & Pal, S. K. (2022). Picosecond-resolved fluorescence resonance energy transfer (FRET) in diffuse reflectance spectroscopy explores biologically relevant hidden molecular contacts in a non-invasive way. Physical chemistry chemical physics : PCCP, 24(10), 6176-6184.More infoThe potentiality of Förster resonance energy transfer (FRET) for studying molecular interactions inside biological tissues with improved spatial (Angström) and temporal (picosecond) resolution is well established. On the other hand, the efficacy of diffuse reflectance spectroscopy (DRS) that uses optical radiation in order to determine physiological parameters including haemoglobin, and oxygen saturation is well known. Here we have made an attempt to combine diffuse reflectance spectroscopy (DRS) with picosecond-resolved FRET in order to show improvement in the exploration of molecular contacts in biological tissue models. We define the technique as ultrafast time-resolved diffuse reflectance spectroscopy (UTRDRS). The illuminated photon of the fluorophore from the surface of the tissue-mimicking layers carries the hidden information of the molecular contact. In order to investigate the validation of the Kubelka-Munk (KM) formulism for the developed UTRDRS technique in tissue phantoms, we have studied the propagation of incandescent and picosecond-laser light through several layers of cellulose membranes. While picosecond-resolved FRET in the diffuse reflected light confirms the hidden nano-contact (4.6 nm) of two different dye layers (8-anilino-1-naphthalenesulfonic acid and Nile blue), high-resolution optical microscopy on the cross-section of the layers reveals the proximity and contacts of the layers with limited spatial resolution (∼300 nm). We have also investigated two biologically relevant molecules, namely carboxyfluorescein and haemoglobin, in tissue phantom layers in order to show the efficacy of the UTRDRS technique. Overall, our studies based on UTRDRS in tissue mimicking layers may have potential applications in non-invasive biomedical diagnosis for patients suffering from skin diseases.
- Kazui, T., Hsu, C. H., Hamidi, M., Acharya, D., Shanmugasundaram, M., Lee, K., Chatterjee, A., & Bull, D. (2022). Five-meter walk test before transcatheter aortic valve replacement and 1-year noncardiac mortality. JTCVS open, 12, 103-117.More infoThe purpose of this study is to assess whether the 5-m walk test is associated with 1-year mortality after transcatheter aortic valve replacement.
- Kazui, T., Hsu, C., Hamidi, M., Acharya, D., Shanmugasundaram, M., Lee, K., Chatterjee, A., & Bull, D. A. (2021). Pre-transcatheter aortic valve replacement 5-meter-walk test score and 1-year noncardiac mortality. Journal of Thoracic and Cardiovascular Surgery.
- Mukherjee, A., Wiener, H. W., Griffin, R. L., Lenneman, C., Chatterjee, A., Nabell, L. M., Lewis, C. E., & Shrestha, S. (2022). Racial and rural-urban disparities in cardiovascular risk factors among patients with head and neck cancer in a clinical cohort. Head & neck, 44(7), 1563-1575.More infoEvidence on distribution of cardiovascular disease (CVD) risk factors in patients with head and neck squamous cell carcinoma (HNSCC) is limited. We assessed disparities in prevalence and incidence of CVD risk factors in patients with HNSCC.
- Mukherjee, A., Wiener, H. W., Griffin, R. L., Lenneman, C., Chatterjee, A., Nabell, L. M., Lewis, C. E., & Shrestha, S. (2022). Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients. Frontiers in cardiovascular medicine, 9, 1024846.More infoRisk of incident cardiovascular disease (CVD) in head and neck squamous cell carcinoma (HNSCC) patients is under-reported. We assessed the association of HNSCC-related factors and traditional risk factors with 1- and 5-year CVD risk in HNSCC patients without prevalent CVD at cancer diagnosis.
- Shanmugasundaram, M., Chatterjee, A., & Lee, K. (2022). Percutaneous Large Thrombus and Vegetation Evacuation in the Catheterization Laboratory. Interventional cardiology clinics, 11(3), 349-358.More infoIntracardiac and intravascular thrombi are associated with significant morbidity and mortality. Although surgery remains the gold standard treatment option, these patients often have multiple comorbidities that can make surgical options challenging. With advancements in catheter-based technologies, there are now percutaneous treatment options for these patients. The AngioVac is a percutaneous vacuum-assisted thrombectomy device FDA-approved for removal of intravascular debris that uses a venovenous extracorporeal membranous oxygenation circuit with a filter. Use of this device has now been reported in the removal of right atrial or iliocaval thrombi, debulking tricuspid vegetations, removal of vegetations from implantable cardiac devices, and pulmonary embolism.
- Acharya, D., Loyaga-Rendon, R. Y., Chatterjee, A., Rajapreyar, I., & Lee, K. (2021). Optical Coherence Tomography in Cardiac Allograft Vasculopathy: State-of-the-Art Review. Circulation. Heart failure, 14(9), e008416.More infoCardiac allograft vasculopathy (CAV) is a challenging complication of heart transplantation. CAV pathophysiology is incompletely understood, standard screening modalities such as angiography have significant limitations, and currently available therapies have only modest efficacy in preventing progression. Optical coherence tomography is a light-based technique that provides microscopic level catheter-based intravascular imaging and has dramatically expanded our understanding of CAV, demonstrating it to be a complex, heterogeneous, and dynamic process. This review covers characteristics and uses of optical coherence tomography, including vessel characterization, serial use to assess progression of disease, guiding percutaneous intervention, and monitoring response to CAV therapies. We also discuss the potential of optical coherence tomography in providing individualized assessment and enable customized CAV therapies, which may lead to improvements in long-term transplant outcomes.
- Baldwin, N. K., Ives, C. W., Morgan, W. S., Bowman, M. H., & Chatterjee, A. (2021). Small Bowel Obstruction Mimicking Acute Inferior ST-Elevation Myocardial Infarction. The American journal of medicine, 134(5), 599-602.
- Chatterjee, A., & Skinner, K. (2021). Crushed Prasugrel Improves Pharmacodynamics But Little Else: Where Are the Missing Pieces?. JACC. Cardiovascular interventions, 14(12), 1334-1336.
- Cruz Rodriguez, J. B., Chatterjee, A., Pamboukian, S. V., Tallaj, J. A., Joly, J., Lenneman, A., Aryal, S., Hoopes, C. W., Acharya, D., & Rajapreyar, I. (2021). Persistent mitral regurgitation after left ventricular assist device: a clinical conundrum. ESC heart failure, 8(2), 1039-1046.More infoPersistent mitral valve regurgitation (MR) after continuous flow left ventricular assist device implantation (cfLVAD) is associated with pulmonary hypertension and right ventricular failure with variable effects on survival across published studies. The aim of this study is to determine the incidence and predictors of persistent MR at 6-month follow-up after cfLVAD implantation and its impact on survival, haemodynamics, right ventricular function, and morbidity.
- Elbadawi, A., Elgendy, I. Y., Albaeni, A., Aly, A., Almustafa, A., Shahin, H. I., Chatterjee, A., Alkhouli, M., Khalife, W., Kapadia, S., & Jneid, H. (2021). Trends and Outcomes of Transcatheter Valve Implantation in Patients With Prior Mediastinal Radiation. The American journal of cardiology, 143, 167-168.
- Law, M. A., & Chatterjee, A. (2021). Transcatheter pulmonic valve implantation: Techniques, current roles, and future implications. World journal of cardiology, 13(5), 117-129.More infoRight ventricular outflow tract (RVOT) obstruction is present in a variety of congenital heart disease states including tetralogy of Fallot, pulmonary atresia/stenosis and other conotruncal abnormalities After surgical repair, these patients develop RVOT residual abnormalities of pulmonic stenosis and/or insufficiency of their native outflow tract or right ventricle to pulmonary artery conduit. There are also sequelae of other surgeries like the Ross operation for aortic valve disease that lead to right ventricle to pulmonary artery conduit dysfunction. Surgical pulmonic valve replacement (SPVR) has been the mainstay for these patients and is considered standard of care. Transcatheter pulmonic valve implantation (TPVI) was first reported in 2000 and has made strides as a comparable alternative to SPVR, being approved in the United States in 2010. We provide a comprehensive review in this space-indications for TPVI, detailed procedural facets and up-to-date review of the literature regarding outcomes of TPVI. TPVI has been shown to have favorable medium-term outcomes free of re-interventions especially after the adoption of the practice of pre-stenting the RVOT. Procedural mortality and complications are uncommon. With more experience, recognition of risk of dreaded outcomes like coronary compression has improved. Also, conduit rupture is increasingly being managed with transcatheter tools. Questions over endocarditis risk still prevail in the TPVI population. Head-to-head comparisons to SPVR are still limited but available data suggests equivalence. We also discuss newer valve technologies that have limited data currently and may have more applicability for treatment of native dysfunctional RVOT substrates.
- Lee, K. S., Chatterjee, A., & Acharya, D. (2021). De-Escalation of DAPT After ACS: Escalating the Odds of Getting It Right. Journal of the American College of Cardiology, 78(8), 778-780.
- Mukherjee, A., Pakhchanian, H., Raiker, R., Singh, S., & Chatterjee, A. (2021). Burden of Thrombotic Events in Coronavirus Disease-19 (COVID-19) Patients and Effect on Outcomes (from a Multicenter Electronic Health Record Database). The American journal of cardiology, 147, 150-152.
- Pakhchanian, H., Raiker, R., Mukherjee, A., Khan, A., Singh, S., & Chatterjee, A. (2021). Outcomes of COVID-19 in CKD Patients: A Multicenter Electronic Medical Record Cohort Study. Clinical journal of the American Society of Nephrology : CJASN, 16(5), 785-786.
- Rajapreyar, I., Joly, J., Tallaj, J., Pamboukian, S. V., Assad, A. H., Lenneman, C., Litovsky, S., Chatterjee, A., Hoopes, C., & Lenneman, A. (2021). Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia. Mayo Clinic proceedings. Innovations, quality & outcomes, 5(1), 210-218.More infoPulmonary hypertension (PH) has been described in myeloproliferative disorders; monoclonal plasma cell disorder such as polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome; and plasma cell dyscrasias such as multiple myeloma and amyloidosis. We describe 4 cases of PH likely due to pulmonary vascular involvement and myocardial deposition from light chain deposition disease, amyloidosis, and multiple myeloma. On the basis of our clinical experience and literature review, we propose screening for plasma cell dyscrasia in patients with heart failure with preserved ejection fraction, unexplained PH, and hematological abnormalities. We also recommend inclusion of cardiopulmonary screening in patients with monoclonal gammopathy of undetermined significance.
- Chatterjee, A. (2020). Comparison of Transcatheter Pulmonic Valve Implantation With Surgical Pulmonic Valve Replacement in Adults (from the National Inpatient Survey Dataset). The American Journal of Cardiology.
- Chatterjee, A. (2020). Small Bowel Obstruction Mimicking Acute Inferior ST-Elevation Myocardial Infarction. The American Journal of Medicine.
- Chatterjee, A., Miller, N. J., Cribbs, M. G., Mukherjee, A., & Law, M. A. (2020). Systematic review and meta-analysis of outcomes of anatomic repair in congenitally corrected transposition of great arteries. World journal of cardiology, 12(8), 427-436.More infoTreatment of congenitally corrected transposition of great arteries (cc-TGA) with anatomic repair strategy has been considered superior due to restoration of the morphologic left ventricle in the systemic circulation. However, data on long term outcomes are limited to single center reports and include small sample sizes.
- Elbadawi, A., Albaeni, A., Elgendy, I. Y., Ogunbayo, G. O., Jimenez, E., Cornwell, L., Chatterjee, A., Khalife, W., Alkhouli, M., Kapadia, S. R., & Jneid, H. (2020). Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Mediastinal Radiation. JACC. Cardiovascular interventions, 13(22), 2658-2666.More infoThis study sought to evaluate the trends and outcomes of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) among patients with prior mediastinal radiation from a national database.
- Matos Santana, H., Heindl, B., Suri, S., Khatoon, S., Aryal, S., Chatterjee, A., Litovsky, S., Ahmed, H., Schnell, A., & Rajapreyar, I. (2020). A Case of Heart Failure in a Patient With Systemic Lupus Erythematosus. JACC. Case reports, 2(3), 414-419.More infoPatients with systemic lupus erythematosus (SLE) can present with multiple cardiovascular pathologies, including pulmonary hypertension, valvular disease, pericarditis, myocarditis, and premature atherosclerosis. SLE medications can also cause cardiovascular side effects. We present a patient who developed a severe cardiomyopathy secondary to the hydroxychloroquine prescribed to treat her SLE. ().
- Chatterjee, A. (2019). Intravascular ultrasound of normal left main arteries: Insights for stent optimization and standardization. Catheterization and Cardiovascular Interventions.
- Marian, M. J., Abu Daya, H., Chatterjee, A., Al Solaiman, F., Sasse, M. F., Fonbah, W. S., Workman, R. W., Johnson, B. E., Carlson, S. E., Brott, B. C., Prabhu, S. D., & Leesar, M. A. (2019). Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial. Journal of the American Heart Association, 8(23), e012844.More infoBackground After a loading dose of ticagrelor, the rate of high on-treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury. This indicates that faster platelet inhibition with crushed ticagrelor (CTIC) or eptifibatide is needed to reduce high on-treatment platelet reactivity. The efficacy of CTIC versus eptifibatide bolus plus clopidogrel is unknown. Methods and Results A total of 100 P2Y naïve, troponin-negative patients with acute coronary syndrome were randomized to CTIC (180 mg) versus eptifibatide bolus (180 μg/kg×2 intravenous boluses) plus clopidogrel (600 mg) at the time of percutaneous coronary intervention. High on-treatment platelet reactivity was markedly higher with CTIC versus eptifibatide bolus plus clopidogrel (42% versus 0%;
- Chatterjee, A. (2018). Embolic stroke of undetermined source and patent foramen ovale closure: Practice insights from meta-analysis?. Catheterization and Cardiovascular Interventions.
- Chatterjee, A. (2018). Patent foramen ovale closure for cryptogenic stroke: Effective, but only in select patients. Catheterization and Cardiovascular Interventions.
- Chatterjee, A. (2018). Patient preference: An important emerging factor in operator access site selection. Catheterization and Cardiovascular Interventions.
- Chatterjee, A. (2018). Surgical aortic valve replacement and transcatheter aortic valve implantation for severe aortic stenosis: Equipoise remains a tenable assumption. Catheterization and Cardiovascular Interventions.
- Chatterjee, A. (2018). The promise of effective P2Y12 platelet receptor pretreatment: Not crushed yet. Catheterization and Cardiovascular Interventions.
- Chatterjee, A. (2018). “Expanding the frame” for valve-in-valve therapy in small bioprostheses: Encouraging signs for the road ahead. Catheterization and Cardiovascular Interventions.
- Chatterjee, A. (2017). Descending septal branch of right coronary artery: Rare, but important in hypertrophic cardiomyopathy. Cardiovascular Revascularization Medicine.
Presentations
- Seckeler, M., Chatterjee, A., Hoyer, A., Caryl, N., Meziab, O., Chandra, S., Seckeler, M., Chatterjee, A., Hoyer, A., Caryl, N., Meziab, O., & Chandra, S. (2023, May). 3D printing of patient-specific intravascular stents for congenital heart disease – proof of concept. The Society for Cardiovascular Angiography and Interventions 2023 Scientific Sessions. Phoenix, Arizona.
- Seckeler, M., Seckeler, M., Chatterjee, A., Chatterjee, A., Meziab, O., Meziab, O., Camarena, M., Camarena, M., Chandra, S., Chandra, S., Yaddanapudi, K., Yaddanapudi, K., Hoyer, A., Hoyer, A., Caryl, N., & Caryl, N. (2023, May). Not every TIA is a PFO – the importance of other shunts. The Society for Cardiovascular Angiography and Interventions 2023 Scientific Sessions. Phoenix, Arizona.
- Habib, N., Sher, A., Tandon, S., Kubba, S., Insel, M., Chatterjee, A., Seckeler, M., & Rischard, F. (2022, May). To Drain or Not to Drain: Hemodynamic Charcterization of Tamponade in Pulmonary Arterial Hypertension. American Thoracic Society 2022. San Francisco, CA.